Document is current

Article History

Received: 17 October 2024

Accepted: 27 January 2025

First Online: 7 February 2025

Declarations

:

: Study approval for the PET-mpMRI imaging study was obtained from the South Central - Berkshire Research Ethics Committee and United Kingdom Health Regulator Authority (Ethics reference 20/SC/0134). Approval for administration of radioactive substances was obtained from the United Kingdom Administration of Radioactive Substances Advisory Committee. All procedures involving human participants were done in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards and written-informed consent was obtained from all individual participants included in the study. Furthermore, the authors affirm that human research participants provided informed consent for publication of the images displayed in the figures. Institutional ethical approval for retrospective analysis of human tissue was obtained, under R18019. The clinical study was retrospectively registered under Clinicaltrials.gov NCT04807582. The date of Registration– (Initial Release Date) was 03-11-2021 and date of enrolment of the first participant was 19-10-2020.

: .

: EOA is on the Scientific Advisory Board of Radiopharm Theranostics; EOA is inventor of carboxylate imaging agents including FPIA. EA has been a Consultant for Radiopharm Theranostics. SI acknowledges unrestricted educational grant (PhD fellowship) support from Bayer Healthcare.